CorMedix Therapeutics (NASDAQ: CRMD) will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The biopharmaceutical company will also host a corporate update conference call at 8:30 am Eastern Time to provide context on its operational progress and commercialization efforts for its therapeutic products focused on life-threatening conditions.

The announcement serves as a key disclosure event for shareholders, offering insight into the company’s performance in institutional care settings across the United States. CorMedix utilizes a field-based medical and commercial infrastructure deployed in hospitals, clinics, and infusion centers to drive sales and marketing initiatives.

Investors and analysts can participate in the conference call through the following channels:

CorMedix Therapeutics is primarily engaged in developing and commercializing therapeutic products for the prevention and treatment of serious diseases in the US market. The company’s strategy centers on direct engagement within institutional healthcare environments, leveraging its specialized infrastructure to reach critical care providers.

Corporate Overview

Headquartered in Parsippany, New Jersey, CorMedix continues to expand its presence in the US biopharmaceutical sector. The company’s focus remains on addressing unmet medical needs through targeted therapeutic solutions, with a distribution model designed to support complex clinical requirements in hospital and infusion center settings.